163 related articles for article (PubMed ID: 32555508)
1. Identification of important genes and drug repurposing based on clinical-centered analysis across human cancers.
Li Y; Dong YP; Qian YW; Yu LX; Wen W; Cui XL; Wang HY
Acta Pharmacol Sin; 2021 Feb; 42(2):282-289. PubMed ID: 32555508
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence, machine learning, and drug repurposing in cancer.
Tanoli Z; Vähä-Koskela M; Aittokallio T
Expert Opin Drug Discov; 2021 Sep; 16(9):977-989. PubMed ID: 33543671
[No Abstract] [Full Text] [Related]
3. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.
Cheng F; Zhao J; Fooksa M; Zhao Z
J Am Med Inform Assoc; 2016 Jul; 23(4):681-91. PubMed ID: 27026610
[TBL] [Abstract][Full Text] [Related]
4. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.
Mottini C; Napolitano F; Li Z; Gao X; Cardone L
Semin Cancer Biol; 2021 Jan; 68():59-74. PubMed ID: 31562957
[TBL] [Abstract][Full Text] [Related]
5. Drug Repurposing for Cancer Therapy in the Era of Precision Medicine.
K W To K; Cho WCS
Curr Mol Pharmacol; 2022; 15(7):895-903. PubMed ID: 35156588
[TBL] [Abstract][Full Text] [Related]
6. Drug Repurposing in Anticancer Reagent Development.
Chen PC; Liu X; Lin Y
Comb Chem High Throughput Screen; 2017; 20(5):395-402. PubMed ID: 28025934
[TBL] [Abstract][Full Text] [Related]
7. Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
Di J; Zheng B; Kong Q; Jiang Y; Liu S; Yang Y; Han X; Sheng Y; Zhang Y; Cheng L; Han J
Mol Oncol; 2019 Oct; 13(10):2259-2277. PubMed ID: 31408580
[TBL] [Abstract][Full Text] [Related]
8. DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration.
Wang Y; Yang Y; Chen S; Wang J
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33822890
[TBL] [Abstract][Full Text] [Related]
9. Cancer driver drug interaction explorer.
Hartung M; Anastasi E; Mamdouh ZM; Nogales C; Schmidt HHHW; Baumbach J; Zolotareva O; List M
Nucleic Acids Res; 2022 Jul; 50(W1):W138-W144. PubMed ID: 35580047
[TBL] [Abstract][Full Text] [Related]
10. Integration of genetic variants and gene network for drug repurposing in colorectal cancer.
Irham LM; Wong HS; Chou WH; Adikusuma W; Mugiyanto E; Huang WC; Chang WC
Pharmacol Res; 2020 Nov; 161():105203. PubMed ID: 32950641
[TBL] [Abstract][Full Text] [Related]
11. Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.
Yang X; Huang WT; Wu HY; He RQ; Ma J; Liu AG; Chen G
Oncol Rep; 2019 Apr; 41(4):2241-2253. PubMed ID: 30816547
[TBL] [Abstract][Full Text] [Related]
12. Systematically Prioritizing Candidates in Genome-Based Drug Repurposing.
Challa AP; Lavieri RR; Lewis JT; Zaleski NM; Shirey-Rice JK; Harris PA; Aronoff DM; Pulley JM
Assay Drug Dev Technol; 2019; 17(8):352-363. PubMed ID: 31769998
[TBL] [Abstract][Full Text] [Related]
13. Combining repurposed drugs to treat colorectal cancer.
Duarte D; Vale N
Drug Discov Today; 2022 Jan; 27(1):165-184. PubMed ID: 34592446
[TBL] [Abstract][Full Text] [Related]
14. A systematic analysis of FDA-approved anticancer drugs.
Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
[TBL] [Abstract][Full Text] [Related]
15. Can Drug Repurposing Accelerate Precision Oncology?
Schipper LJ; Zeverijn LJ; Garnett MJ; Voest EE
Cancer Discov; 2022 Jul; 12(7):1634-1641. PubMed ID: 35642948
[TBL] [Abstract][Full Text] [Related]
16. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.
Nowak-Sliwinska P; Scapozza L; Ruiz i Altaba A
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):434-454. PubMed ID: 31034926
[TBL] [Abstract][Full Text] [Related]
17. Precision drug repurposing via convergent eQTL-based molecules and pathway targeting independent disease-associated polymorphisms.
Vitali F; Berghout J; Fan J; Li J; Li Q; Li H; Lussier YA
Pac Symp Biocomput; 2019; 24():308-319. PubMed ID: 30864332
[TBL] [Abstract][Full Text] [Related]
18. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND PERSONALISED TREATMENT.
Gligorijević V; Malod-Dognin N; Pržulj N
Pac Symp Biocomput; 2016; 21():321-32. PubMed ID: 26776197
[TBL] [Abstract][Full Text] [Related]
19. Drug repurposing a compelling cancer strategy with bottomless opportunities: Recent advancements in computational methods and molecular mechanisms.
Dash R; Yadav M; Biswal J; Samanta S; Sharma T; Mohapatra S
Indian J Pharmacol; 2023; 55(5):322-331. PubMed ID: 37929411
[TBL] [Abstract][Full Text] [Related]
20. MNBDR: A Module Network Based Method for Drug Repositioning.
Chen HG; Zhou XH
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
